Dr. Sharon Merims
Dr. Sharon Merims is the Head of the Dermato-oncology clinic at the Sharett institute of Oncology, treating patients with a wide range of skin cancers including melanoma, cutaneous lymphoma and non-melanoma skin cancers such as cSCC, BCC and Kaposi’s sarcoma.
Dr. Merims actively promotes collaboration between physicians and researchers, and she is currently working on developing new approaches to treat cutaneous toxicity caused by targeted therapies (such as EGFR inhibitors). To achieve this goal, EMRIS pharma, a start-up, was launched on May 1st of this year with the NGT HealthCare II incubator.
Between 2006-2009, Dr. Merims was a post-doc fellow at the Immunology dept at the University Health Network, Toronto, Ontario Canada, where she led two projects: the Human Translational Project of Adoptive T cell Immunotherapy for Acute Myeloid Leukemia patients using ex vivo expanded double negative T Cells and a study of a rare subtype of gdT cells and developed a method to expand these unique cells.
Dr Merims obtained her M.D from The Hebrew University of Jerusalem and was a Dermatology Resident at the Hadassah Medical Center.